Skip to main content

Table 1 Clinical characteristics of the patients

From: Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist

 

All patients

3 m group

2 m group

1 m group

p-value

n

40

10

10

20

 

Age

70.6 ± 7.0

73.4 ± 7.9

72.1 ± 6.9

68.5 ± 6.2

0.147

BW (kg)

64.2 ± 7.9

61.7 ± 6.9

62.0 ± 8.9

66.1 ± 6.8

0.289

Height (cm)

166.6 ± 5.1

166.9 ± 3.4

164.5 ± 6.2

165.9 ± 5.3

0.166

BMI

23.1 ± 2.6

22.1 ± 2.3

22.9 ± 2.9

24.0 ± 2.1

0.295

PSA

12.0 ± 9.9

8.91 ± 7.10

17.6 ± 14.9

10.65 ± 6.84

0.177

GS; n (%)

     6

5 (12)

 

2 (20)

3 (15)

 

     7

22 (55)

7 (70)

4 (40)

11 (55)

 

     8

8 (20)

3 (30)

2 (20)

3 (15)

 

     9

5 (13)

 

2 (20)

3 (15)

 

TNM classification; n (%)

T1cN0M0

5 (13)

 

2 (20)

3 (15)

 

T2N0M0

22 (55)

8 (80)

4 (40)

10 (50)

 

T3N0M0

13 (33)

2 (20)

4 (40)

7 (35)

 

D’Amico risk classification; n (%)

low

2 (7)

 

1 (10)

1 (5)

 

intermediate

12 (40)

3 (30)

2 (20)

7 (35)

 

poor

16 (53)

7 (70)

7 (70)

12 (60)

 
  1. Data are presented as means ± SD unless indicated otherwise
  2. BW body weight; BMI Body Mass Index; PSA prostatic specific antigen; GS Gleason score; SD standard deviation